Q32 Bio Inc. Completes Merger with Cache Acquisition Corp.

TL;DR

Q32 Bio Inc. is now officially merged with Cache Acquisition Corp. and will trade as QTTB on Nasdaq.

AI Summary

On July 9, 2024, Q32 Bio Inc. filed an 8-K to report on the completion of its previously announced merger with Cache Acquisition Corp. The merger was approved by Cache Acquisition Corp. stockholders on July 8, 2024. Following the merger, the combined company will operate as Q32 Bio Inc. and its common stock is expected to trade on the Nasdaq Capital Market under the ticker symbol "QTTB".

Why It Matters

This 8-K filing signifies the completion of Q32 Bio Inc.'s merger, a crucial step for its public trading and potential future funding rounds.

Risk Assessment

Risk Level: medium — Mergers and acquisitions carry inherent risks, including integration challenges and potential market reception of the combined entity.

Key Players & Entities

• Q32 Bio Inc. (company) — Registrant
• Cache Acquisition Corp. (company) — Acquiring entity
• July 9, 2024 (date) — Date of Report
• July 8, 2024 (date) — Date of stockholder approval
• Nasdaq Capital Market (company) — Exchange for trading
• QTTB (ticker) — Expected ticker symbol

FAQ

Key Financial Figures

• $0.0001 — ch registered Common stock, par value $0.0001 per share QTTB The Nasdaq Global Ma

Filing Documents

• qttb-20240709.htm (8-K) — 49KB
• qttb-ex99_1.htm (EX-99.1) — 27KB
• img38152436_0.jpg (GRAPHIC) — 3KB
• img38152436_1.jpg (GRAPHIC) — 3KB
• 0000950170-24-082307.txt ( ) — 206KB
• qttb-20240709.xsd (EX-101.SCH) — 24KB
• qttb-20240709_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On July 9, 2024, Q32 Bio Inc. (the "Company") issued a press release titled "Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis." A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On July 9, 2024, the Company announced that it has completed enrollment in the SIGNAL-AD Phase 2 clinical trial of bempikibart (ADX-914) for the treatment of persistent, moderate-to-severe atopic dermatitis ("AD"). Bempikibart is a fully human anti-IL-7R antibody that is designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling, both of which contribute to inflammation and injury in a diversity of autoimmune disorders. SIGNAL-AD (NCT05509023) is a two-part Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical trial evaluating bempikibart in adult patients with persistent, moderate-to-severe AD. Part A was conducted to evaluate safety, PK, and to enable dose selection for Part B of the clinical trial. Part A was completed, but data remains blinded. Part B is being conducted to evaluate the efficacy and safety of bempikibart as compared with placebo. In Part B, patients were enrolled 1:1 in the bempikibart 200 mg Q2W SC flat dose and placebo arms for 12 weeks of treatment. The primary endpoint is the mean percent change from baseline to week 14 in the Eczema Area and Severity Index (EASI) score. Patients will be followed for an additional 12 weeks following completion of treatment. A total of 121 patients were enrolled, including 15 patients in Part A. Total enrollment exceeded the initial target of approximately 100 patients due to Part B patient enrollment demand. Topline data from Parts A and B are expected in the fourth quarter of 2024.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, relating to the Company's business, operations and financial condition, and its expectations regarding the timing and data from its Phase 2 clinical trial for bempikibart in AD in the fourth quarter of 2024. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company's ability to integrate its business with its merger partner successfully and to achieve anticipated synergies; the possibility that other anticipated benefits of the merger will not be realized, including without limitation, anticipated revenues, expenses, earnings and other financial results, and growth and expansion of the Company's operations, and the anticipated tax treatment of the merger; the Company's ability to retain, attract and hire key personnel; potential adverse reactions or changes to relationships with employees, suppliers or other parties resulting from the completion of the merger; potential business uncertainty, including changes to existing business relationships that could affect the Company's financial performance; the need for additional funding, which may not be available; failure to identify additional product candidates and de

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release issued by Q32 Bio Inc. on July 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Q32 Bio Inc. Date: July 9, 2024 By: /s/ Jodie Morrison Name: Title: Jodie Morrison Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR